Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008
Published online before print July 24, 2008, doi: 10.1161/CIRCRESAHA.108.179861
A more recent version of this article appeared on August 29, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
103/5/450    most recent
CIRCRESAHA.108.179861v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mansouri, R. M.
Right arrow Articles by Fruchart, J.-C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mansouri, R. M.
Right arrow Articles by Fruchart, J.-C.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Lipid and lipoprotein metabolism
Right arrow Mechanism of atherosclerosis/growth factors
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Gene regulation
Right arrow Genetically altered mice

Submitted on May 21, 2008
Revised on June 18, 2008
Accepted on July 15, 2008

Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia

Roxane M. Mansouri ; Eric Baugé ; Philippe Gervois ; Jamila Fruchart-Najib ; Catherine Fiévet ; Bart Staels *; and Jean-Charles Fruchart

From the Institut Pasteur de Lille, Inserm U545, Faculté des Sciences Pharmaceutiques et Biologiques, Université de Lille 2, France.

* To whom correspondence should be addressed. E-mail: bart.staels{at}pasteur-lille.fr.

Hypertriglyceridemia is an independent risk factor for coronary artery disease. Because apolipoprotein (Apo)A5 regulates plasma triglyceride levels, we investigated the impact of human (h)ApoA5 on atherogenesis. The influence of hApoA5 transgenic expression was studied in the ApoE2 knock-in mouse model of mixed dyslipidemia. Our results demonstrate that hApoA5 lowers plasma triglyceride levels in Western diet–fed ApoE2 knock-in mice. Moreover, atherosclerotic lesion development was significantly decreased in the hApoA5 transgenic mice. Finally, pharmacologic activation of hApoA5 expression by the peroxisome proliferator-activated receptor-{alpha} agonist fenofibrate resulted in an enhanced atheroprotection. These results identify an atheroprotective role of hApoA5 in a mouse model of mixed dyslipidemia.
Key words: human apolipoprotein A5 • atherosclerosis • dyslipidemia • fibrates • mouse model






Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.